Posted by Michael Wonder on 12 Aug 2020
Takeda expects more effective IBD treatment with Kynteles' expanded reimbursement
12 August 2020 - Takeda Korea is strengthening its position in the domestic inflammatory bowel disease market with Kynteles receiving expanded reimbursement as a first-line treatment, the company said in a news conference Wednesday.
IBD has two most common symptoms -- ulcerative colitis and Crohn's disease. Ulcerative colitis is an inflammatory bowel disease that causes long-lasting inflammation and ulcers in a patient's digestive tract. Crohn's disease can cause inflammation anywhere from the mouth to the anus.
